David Dobrosky

Transition Bio, Inc.

Transition Bio is developing one-of-a-kind technologies for biomolecular condensate analysis. Through our Condensomics platform, our goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. We harness droplet microfluidic approaches and cellular platforms to characterize condensates with unprecedented scale and precision, resulting in the mapping of condensates and their modulation, in molecular detail. Our proprietary datasets feed in to algorithms that we use for target discovery, target validation and drug design.